Markets
Apple CEO Tim Cook
(Beata Zawrzel/NurPhoto via Getty Images)
S-word

Analyst slaps a rare “sell” rating on Apple

Apple watcher Craig Moffett made the call in light of what he calls “a steady drumbeat of bad news.”

Matt Phillips

Don’t be fooled by the 10% run-up in share price over the last three months, says tech analyst Craig Moffett. The upturn in Apple has come amid a drip, drip, drip of downbeat headlines that threaten to weigh on the company going forward, he wrote.

“A Federal Judge (Amit Mehta) had declared the payments Google makes to Apple each year for Google’s preferred (default) search position to be illegal. Apple’s position in China has steadily weakened. The Vision Pro, already expected to be something of a bust, has disappointed even the low expectations that had been set for it. And while the incoming Trump Administration is likely to exempt Apple from import tariffs, there is a genuine risk that Apple will be targeted with retaliatory tariffs in countries negatively impacted by U.S. import duties in unrelated categories.”

But most worrisome, Moffett says, is the “the lukewarm (we’re being charitable here) response consumers have given Apple’s first suite of AI features.”

For the record, as of yesterday, two-thirds of the analysts covering Apple still have a buy or overweight rating on the stock, though that’s down from nearly 80% that saw Apple as a buy back in January 2023. And while the Street seems bullish on the surface, the average 12-month price target is less than 2% above where the iPhone maker is currently trading.

Moffett is the senior research analyst at MoffettNathanson, an independent research provider specializing in the TMT sectors. His price target of $188 implies a more than 20% decline for Apple.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.